Ashton, N. J. https://orcid.org/0000-0002-3579-8804
Leuzy, A.
Karikari, T. K.
Mattsson-Carlgren, N.
Dodich, A.
Boccardi, M.
Corre, J.
Drzezga, A.
Nordberg, A.
Ossenkoppele, R.
Zetterberg, H.
Blennow, K.
Frisoni, G. B.
Garibotto, V.
Hansson, O.
Funding for this research was provided by:
University of Gothenburg
Article History
Received: 3 November 2020
Accepted: 9 February 2021
First Online: 6 March 2021
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx; has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, Biogen, Cerveau and Roche. VG received financial support for research through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck and consultancy/speaker fees from Siemens Healthineers and GE Healthcare. NJA, AL, TKK, NMC, AD, MB, CJ and GBF report no conflicts of interest.